Unknown

Dataset Information

0

Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China.


ABSTRACT: In China, HIV-1-infected patients typically receive antiretroviral therapy (ART) that includes lamivudine (3TC) as a reverse-transcriptase inhibitor (RTI) (ART-3TC). Previous studies from certain developed countries have shown that, in ART-3TC, 3TC-resistant HBV progressively emerges at an annual rate of 15-20% in patients coinfected with HIV-1 and HBV. This scenario in China warrants investigation because >10% of all HIV-infected patients in China are HBV carriers. We measured the occurrence of 3TC-resistant HBV during ART-3TC for HIV-HBV coinfection and also tested the effect of tenofovir disoproxil fumarate (TDF) used as an additional RTI (ART-3TC/TDF) in a cohort study in China. We obtained 200 plasma samples collected from 50 Chinese patients coinfected with HIV-1 and HBV (positive for hepatitis B surface antigen) and examined them for the prevalence of 3TC-resistant HBV by directly sequencing PCR products that covered the HBV reverse-transcriptase gene. We divided the patients into ART-3TC and ART-3TC/TDF groups and compared the efficacy of treatment and incidence of drug-resistance mutation between the groups. HIV RNA and HBV DNA loads drastically decreased in both ART-3TC and ART-3TC/TDF groups. In the ART-3TC group, HBV breakthrough or insufficient suppression of HBV DNA loads was observed in 20% (10/50) of the patients after 96-week treatment, and 8 of these patients harbored 3TC-resistant mutants. By contrast, neither HBV breakthrough nor treatment failure was recorded in the ART-3TC/TDF group. All of the 3TC-resistant HBV mutants emerged from the cases in which HBV DNA loads were high at baseline. Our results clearly demonstrated that ART-3TC is associated with the emergence of 3TC-resistant HBV in patients coinfected with HIV-1 and HBV and that ART-3TC/TDF reduces HBV DNA loads to an undetectable level. These findings support the use of TDF-based treatment regimens for patients coinfected with HIV-1 and HBV.

SUBMITTER: Gu L 

PROVIDER: S-EPMC4543549 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

altmetric image

Publications

Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China.

Gu Lijun L   Han Yang Y   Li Yijia Y   Zhu Ting T   Song Xiaojing X   Huang Ying Y   Yang Feifei F   Guan Shuo S   Xie Jing J   Gohda Jin J   Hosoya Noriaki N   Kawana-Tachikawa Ai A   Liu Wenjun W   Gao George Fu GF   Iwamoto Aikichi A   Li Taisheng T   Ishida Takaomi T  

PloS one 20150819 8


In China, HIV-1-infected patients typically receive antiretroviral therapy (ART) that includes lamivudine (3TC) as a reverse-transcriptase inhibitor (RTI) (ART-3TC). Previous studies from certain developed countries have shown that, in ART-3TC, 3TC-resistant HBV progressively emerges at an annual rate of 15-20% in patients coinfected with HIV-1 and HBV. This scenario in China warrants investigation because >10% of all HIV-infected patients in China are HBV carriers. We measured the occurrence of  ...[more]

Similar Datasets

| S-EPMC3239326 | biostudies-literature
| S-EPMC3324378 | biostudies-literature
| S-EPMC3409123 | biostudies-literature
| S-EPMC6173268 | biostudies-literature
| S-EPMC7354521 | biostudies-literature
| S-EPMC5106338 | biostudies-literature
| S-EPMC6130076 | biostudies-literature
| S-EPMC3292846 | biostudies-literature
| S-EPMC2894418 | biostudies-literature
| S-EPMC5573866 | biostudies-literature